Literature DB >> 2605621

Adequate heparinization during PTCA: assessment using activated clotting times.

J D Ogilby1, H A Kopelman, L W Klein, J B Agarwal.   

Abstract

Heparinization during PTCA is often done empirically with an initial 10,000 unit bolus of heparin and subsequent additional boluses as deemed necessary to prevent thrombus formation and fibrin deposition. However, the initial 10,000 unit bolus may not result in adequate systemic anticoagulation in every patient, exposing some patients to risk of thrombus at the angioplasty site and subsequent reocclusion. In this non-randomized study, we assessed systemic coagulation during PTCA by retrospectively analyzing activated clotting times obtained in 108 consecutive patients. All patients had normal baseline prothrombin times and activated partial thromboplastin times. Patients who were on heparin prior to PTCA were excluded. Based on data from studies on heparinization during extracorporeal bypass an activated clotting time (ACT) of greater than 300 seconds was required. Twelve patients (11%) were observed to have activated clotting times of below 300 seconds after an initial 10,000 unit bolus of heparin. These patients required an additional 3,000-10,000 units of heparin to have systemic anticoagulation during PTCA. Symptoms of stable or unstable angina had no significant effect on heparin requirement, although there was a trend toward greater heparin resistance in unstable angina. We conclude that it is important to monitor the status of anticoagulation during PTCA, for 11% of patients undergoing PTCA require additional initial heparin bolus to achieve an ACT greater than 300 seconds and to be effectively anticoagulated. Careful monitoring of heparinization during PTCA may reduce the incidence of thrombosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2605621     DOI: 10.1002/ccd.1810180403

Source DB:  PubMed          Journal:  Cathet Cardiovasc Diagn        ISSN: 0098-6569


  10 in total

1.  Monitoring Anticoagulation During Percutaneous Coronary Interventions.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Antithrombotic Therapy during Percutaneous Coronary Intervention.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention.

Authors:  S Tsimikas; R Beyer; A Hassankhani
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

4.  Activated clotting time or activated partial thromboplastin time as the method of choice for patients undergoing neuroradiological intervention.

Authors:  R Kubalek; A Berlis; M Schwab; J Klisch; M Schumacher
Journal:  Neuroradiology       Date:  2003-03-28       Impact factor: 2.804

5.  Safety of low dose heparin in elective coronary angioplasty.

Authors:  K T Koch; J J Piek; R J de Winter; G K David; K Mulder; J G Tijssen; K I Lie
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

6.  All ACTs are not created equal.

Authors:  J J Ferguson
Journal:  Tex Heart Inst J       Date:  1992

Review 7.  Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery.

Authors:  Colleen E Gruenwald; Cedric Manlhiot; Lynn Crawford-Lean; Celeste Foreman; Leonardo R Brandão; Brian W McCrindle; Helen Holtby; Ross Richards; Helen Moriarty; Glen Van Arsdell; Anthony K Chan
Journal:  J Extra Corpor Technol       Date:  2010-03

Review 8.  Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.

Authors:  J Bowers; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1993

9.  Clinical Experience with Routine Activated Coagulation Time Monitoring During Elective PTCA.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

10.  Efficacy of the hemostatic device VasoSTAT and the study of hemostatic factor.

Authors:  Hirokazu Naganawa; Akira Ito; Shinrou Saiki; Daisuke Nishi; Shinichi Takamatsu; Yoshihisa Ito; Takeshi Suzuki
Journal:  Sci Rep       Date:  2021-11-01       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.